简介：ObjectivesTocomparetheefficiencyoffourcommercialELISAkitsindetectingtype-specificHSV-2IgGantibodies.MaterialsandMethods:Atotalof125subjects,including105withgenitalulcers,and20controlswithoutanyhistoryofSTDswererecruitedfromtheSTDclinicfordetectionoftype-specificHSV-2IgGantibodywithdifferentkits.FourkindsofcommerciallyavailableELISAkits,includingQuidaHSV2IgGELISA(AifulangBiochemCo.Ltd.,Hangzhou),TORCH-HSV2IgG(JingmeiBiotechCo.Ltd.,Shanghai),Captia^TMHSV2IgG(Trinitybiotech,USA)andHerpeSelectT^TM2ELISAlgG(Focustechnologies,USA)wereusedforevaluation.WesternBlotassaywasperformedasagoldstandard.Results:ComparedtoWesternBlotresults,thesensitivityandspecificityofthekits(QuidaHSV2,TORCHHSV2,Captia^TMHSV2andHerpeSelect^TM2)were13.1%and98.4%,7.5%and100%,100%and11.1%,87.7%and96.7%,respectively.Thepositivepredictivevalue(PV)andnegativePVofthefourkitswere88.9%and54.3%,100%and55.5%,55.6%and100%,96.2%and89.2%,respectively.TheareasundertheROCcurveofthreekits(QuidaHSV2,Captia^TMHSV2andHerpeSelect^TM2)were0.885(0.822-0.948),0.825(0.747-0.902),0.974(0.950--0.998),respectivelyConclusion:TheperformanceofHerpeSelect^TM2isthebestamongthefourkits.Theresultsalsoindicatethatthecommerciallyavailablekitsfordetectionoftype-specificHSV2antibodyshouldbere-evaluatedintermsoftheirvalidity.